The cortical silent period in schizophrenia: A systematic review and meta-analysis focusing on disease stage and antipsychotic medication. (April 2022)

• Record Type: Journal Article
• Authors: Miyazawa, Atsuhiro; Kanahara, Nobuhisa; Shiko, Yuki; Ozawa, Yoshihito; Kawasaki, Yohei; Komatsu, Hiroshi; Masumo, Yuto; Nakata, Yusuke; Iyo, Masaomi
• Is Part Of: Journal of psychopharmacology. Volume 36:Number 4(2022)
• Page Start: 479
• Page End: 488
• Publication Date: 2022-04
• Subjects: Antipsychotic -- cortical inhibition -- GABA -- transcranial magnetic stimulation -- treatment-resistant; Psychopharmacology -- Periodicals; 615.78
• DOI: 10.1177/02698811221078751
• Languages: English
• ISSNs: 0269-8811

Abstract

Background: Although numerous studies reported some changes of cortical silent period (CSP), an indicator of gamma-aminobutyric acid (GABA) function in central nervous system, in schizophrenia patients, it has been unknown how the disease stage and antipsychotic medication affect CSP values. Methods: The present study conducted a systematic review of previous literature comparing CSP between schizophrenia patients and healthy subjects, and then performed meta-analysis on the effects of (1) the disease stage and (2) antipsychotics on CSP. Results: (1) In the comparison of the disease stage comprising a total of 17 reports, there was no significant difference in CSP between patients under drug-naïve first-episode psychoses and healthy controls, or between patients with antipsychotic medication and healthy controls. (2) In the comparison of the antipsychotic class, patients treated with clozapine were longer in CSP compared to healthy controls. Patients treated with olanzapine/quetiapine or with other type of antipsychotics were not different from healthy controls. Regarding other type of antipsychotics, the iteration analysis after leaving out one literature showed that patients were shorter in CSP than healthy controls. Conclusion: The results showed that clozapine seems to surely prolong CSP, indicating the enhancement of GABA transmission via GABAB receptors, suggesting the possible relationship between the CSP prolongation by clozapine and its high efficacy in psychopathology. The finding of shorter CSP in patients with other type of antipsychotics was distinct from clozapine/olanzapine/quetiapine, but was difficult to interpret since this group included a variety of transcranial magnetic stimulation (TMS) methodologies and patients' background.